Tempus AI, Inc. (TEM) EBITDA Margin: -17.48%
Is Tempus AI, Inc.’s EBITDA margin high or low?
Tempus AI, Inc.'s EBITDA margin of -17.48% is 72% above its 5-year average of -63.28%, near the high end of its 5-year range (-90.09%–-17.48%).
As of Saturday, June 13, 2026. 66.87% above its 12-month average of -52.76%.
TEM EBITDA Margin Chart
TEM Average EBITDA Margin Chart
TEM Current vs Average EBITDA Margin Chart
TEM EBITDA Margin Metrics
EBITDA MARGIN
-17.48%
EBITDA MARGIN AVG TTM
-52.76%
EBITDA MARGIN AVG 3Y
-51.11%
EBITDA MARGIN AVG 5Y
-63.28%
EBITDA MARGIN AVG 10Y
-77.24%
EBITDA MARGIN AVG 15Y
-77.24%
EBITDA MARGIN AVG 20Y
-77.24%
CURRENT VS TTM AVG
+66.87%
CURRENT VS 3Y AVG
+65.80%
CURRENT VS 5Y AVG
+72.38%
CURRENT VS 10Y AVG
+77.37%
CURRENT VS 15Y AVG
+77.37%
CURRENT VS 20Y AVG
+77.37%
TEM Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.35B | -17.48% | -52.76% | -51.11% | -63.28% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.73B | 48.39% | -17.53% | -54.94% | 28.49% |
| Charles River Laboratories International, Inc. (CRL) | $9.03B | 10.23% | 12.29% | 18.59% | 20.64% |
| Walgreens Boots Alliance, Inc. (WBA) | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Hims & Hers Health, Inc. (HIMS) | $5.98B | 7.60% | 6.80% | 0.29% | -7.92% |
| Baxter International Inc. (BAX) | $10.77B | 6.81% | 8.65% | 4.13% | 9.00% |
| Align Technology, Inc. (ALGN) | $12.52B | 18.98% | 19.70% | 20.24% | 21.46% |
| The Cooper Companies, Inc. (COO) | $13.24B | 25.74% | 26.63% | 26.11% | 26.16% |
| Solventum Corporation (SOLV) | $13.66B | 30.62% | 24.56% | 26.05% | 27.07% |
| DENTSPLY SIRONA Inc. (XRAY) | $2.02B | -1.25% | -7.46% | -6.38% | 1.15% |
Margin Comparison
Gross Margin
69.5%
EBITDA Margin
-17.5%
Operating Margin
-18.1%
Net Margin
-22.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Tempus AI, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Tempus AI, Inc. (TEM)?
- The EBITDA margin for TEM stock is -17.48%.
- Is Tempus AI, Inc.'s EBITDA margin high or low?
- Tempus AI, Inc.'s EBITDA margin of -17.48% is 72% above its 5-year average of -63.28%, near the high end of its 5-year range (-90.09%–-17.48%).
- What is the TTM average EBITDA margin for Tempus AI, Inc. (TEM)?
- The TTM average EBITDA margin for TEM stock is -52.76%.
- What is the 3Y average EBITDA margin for Tempus AI, Inc. (TEM)?
- The 3Y average EBITDA margin for TEM stock is -51.11%.
- What is the 5Y average EBITDA margin for Tempus AI, Inc. (TEM)?
- The 5Y average EBITDA margin for TEM stock is -63.28%.
- What is the 10Y average EBITDA margin for Tempus AI, Inc. (TEM)?
- The 10Y average EBITDA margin for TEM stock is -77.24%.
- What is the 15Y average EBITDA margin for Tempus AI, Inc. (TEM)?
- The 15Y average EBITDA margin for TEM stock is -77.24%.
- What is the 20Y average EBITDA margin for Tempus AI, Inc. (TEM)?
- The 20Y average EBITDA margin for TEM stock is -77.24%.
Tempus AI, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -17.48% |
| 2024-12-31 | -88.03% |
| 2023-12-31 | -25.07% |
| 2022-12-31 | -73.86% |
| 2021-12-31 | -85.13% |
| 2020-12-31 | -90.09% |
| 2019-12-31 | -160.99% |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky